Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119

BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER

Gottesman, M. M., & PASTAN, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,569

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

Campo, E., Swerdlow, S. H., Harris, N. L., Pileri, S. A., Stein, H., & Jaffe, E. S. (2011) · Blood · doi:10.1182/blood-2011-01-293050 · Cited by 2,007

Myelodysplastic Syndromes

Greenberg, P. L., Attar, E. C., Bennett, J. M., Bloomfield, C. D., Borate, U., Castro, C. M. D., Deeg, H. J., Frankfurt, O., Gaensler, K. M. L., Garcia-Manero, G., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0104 · Cited by 1,625

Age and acute myeloid leukemia

Appelbaum, F. R., Gundacker, H. M., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,371

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Bloomfield, C. D., Lawrence, D. D., Byrd, J. C., Carroll, A. J., Pettenati, M. J., Tantravahi, R. V., Patil, S., Davey, F. R., Berg, D. T., Schiffer, C. A., et al. (1998) · PubMed · Cited by 682

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301713 · Cited by 487

Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges

Shallis, R. M., Wang, R., Davidoff, A. J., Ma, X., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.04.005 · Cited by 980

Osteosarcoma

Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Dinardo, C. D., Maiti, A., Rausch, C. R., Pemmaraju, N., Naqvi, K., Daver, N. G., Kadia, T. M., Borthakur, G. M., Ohanian, M. N., Alvarado, Y., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30210-6 · Cited by 324

How I treat acute myeloid leukemia in the era of new drugs

Dinardo, C. D., & Wei, A. H. (2019) · Blood · doi:10.1182/blood.2019001239 · Cited by 293

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Short, N. J., Bravo, G. M., Hwang, H., Ning, J., Franquiz, M. J., Kanagal‐Shamanna, R., Patel, K. P., Dinardo, C. D., Ravandi, F., Garcia‐Manero, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003120 · Cited by 188

Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes

Matsukawa, T., Yoshida, S. Y., Onozawa, M., Fujii, F., Nagai, J., Takahashi, T., Ota, S., Hashiguchi, J., Mori, A., Miyagishima, T., et al. (2026) · Figshare · doi:10.6084/m9.figshare.31310112

Differential Induction Among Younger Patients Diagnosed with Secondary Acute Myelogenous Leukemia Is Feasible By Cytogenetic/Molecular Risk Stratification

Afrough, A., Talukder, R., Yellapragada, S. V., Teegavarapu, P. S., Mims, M. P., & Rivero, G. (2019) · Blood · doi:10.1182/blood-2019-129183

Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML

Lalayanni, C., Gavriilaki, E., Athanasiadou, A., Iskas, M., Papathanasiou, M., Marvaki, A., Dimou-Mpesikli, S., Papaioannou, G., Mallouri, D., Batsis, I., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.09.019 · Cited by 17

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation

Senapati, J., Kantarjian, H. M., Haddad, F., Short, N. J., Borthakur, G. M., Kanagal‐Shamanna, R., Tang, G., Jabbour, E. J., Dinardo, C. D., Daver, N. G., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27561 · Cited by 17

Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk

Kim, S., Yoon, S., Hong, J., Shin, D., Koh, Y., Byun, J. M., & Kim, I. (2020) · Anticancer Research · doi:10.21873/anticanres.14269 · Cited by 17

Stratification of de novo Adult Acute Myelogenous Leukemia with Adverse-Risk Karyotype: Can We Overcome the Worse Prognosis of Adverse-Risk Group Acute Myelogenous Leukemia with Hematopoietic Stem Cell Transplantation?

Yoon, J., Kim, H., Shin, S., Lee, S., Cho, B., Eom, K., Kim, Y., Lee, S., Min, C., Cho, S., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.10.015 · Cited by 8

Characteristics and Outcomes of Secondary Acute Myeloid Leukemia and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Multicenter Study From the Thai Acute Leukemia Study Group

Chanswangphuwana, C., Polprasert, C., Owattanapanich, W., Kungwankiattichai, S., Tantiworawit, A., Rattanathammethee, T., Limvorapitak, W., Saengboon, S., Niparuck, P., Puavilai, T., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.08.010 · Cited by 2

Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML

Schoch, C., Kern, W., Schnittger, S., Hiddemann, W., & Haferlach, T. (2003) · Leukemia · doi:10.1038/sj.leu.2403187 · Cited by 285

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Short, N. J., Venugopal, S., Qiao, W., Kadia, T. M., Ravandi, F., Macaron, W., Dinardo, C. D., Daver, N. G., Konopleva, M. Y., Borthakur, G. M., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01229-z · Cited by 31

Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study

Østgård, L. S. G., Medeiros, B. C., Sengeløv, H., Nørgaard, M., Andersen, M. K., Dufva, I. H., Friis, L. S., Kjeldsen, E., Marcher, C. W., Preiss, B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0890 · Cited by 451